Arcellx Inc
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a prod… Read more
Arcellx Inc (ACLX) - Net Assets
Latest net assets as of September 2025: $440.78 Million USD
Based on the latest financial reports, Arcellx Inc (ACLX) has net assets worth $440.78 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($655.92 Million) and total liabilities ($215.14 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $440.78 Million |
| % of Total Assets | 67.2% |
| Annual Growth Rate | 78.61% |
| 5-Year Change | 799.85% |
| 10-Year Change | N/A |
| Growth Volatility | 207.49 |
Arcellx Inc - Net Assets Trend (2018–2024)
This chart illustrates how Arcellx Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Arcellx Inc (2018–2024)
The table below shows the annual net assets of Arcellx Inc from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $454.79 Million | -6.30% |
| 2023-12-31 | $485.38 Million | +136.82% |
| 2022-12-31 | $204.95 Million | +268.67% |
| 2021-12-31 | $-121.52 Million | -340.43% |
| 2020-12-31 | $50.54 Million | +254.38% |
| 2019-12-31 | $-32.74 Million | -333.91% |
| 2018-12-31 | $14.00 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Arcellx Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 48175300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $53.00K | 0.01% |
| Other Comprehensive Income | $848.00K | 0.19% |
| Other Components | $950.72 Million | 209.04% |
| Total Equity | $454.79 Million | 100.00% |
Arcellx Inc Competitors by Market Cap
The table below lists competitors of Arcellx Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Galaxy Digital Holdings Ltd
NASDAQ:GLXY
|
$4.04 Billion |
|
Hikma Pharmaceuticals PLC
PINK:HKMPF
|
$4.04 Billion |
|
Ambuja Cements Limited
NSE:AMBUJACEM
|
$4.05 Billion |
|
ELF Beauty Inc
NYSE:ELF
|
$4.05 Billion |
|
Brunello Cucinelli S.p.A
OTCGREY:BCUCF
|
$4.04 Billion |
|
Temenos AG
PINK:TMNSF
|
$4.04 Billion |
|
Babcock International Group PLC
PINK:BCKIF
|
$4.03 Billion |
|
FASTIG.AB BALD. B SK 016
F:28F0
|
$4.03 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Arcellx Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 485,380,000 to 454,792,000, a change of -30,588,000 (-6.3%).
- Net loss of 107,348,000 reduced equity.
- Share repurchases of 1,164,000 reduced equity.
- Other comprehensive income increased equity by 301,000.
- Other factors increased equity by 77,623,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-107.35 Million | -23.6% |
| Share Repurchases | $1.16 Million | -0.26% |
| Other Comprehensive Income | $301.00K | +0.07% |
| Other Changes | $77.62 Million | +17.07% |
| Total Change | $- | -6.30% |
Book Value vs Market Value Analysis
This analysis compares Arcellx Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 13.49x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 1.36x to 13.49x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $84.30 | $114.51 | x |
| 2019-12-31 | $-0.94 | $114.51 | x |
| 2020-12-31 | $2.32 | $114.51 | x |
| 2021-12-31 | $-3.62 | $114.51 | x |
| 2022-12-31 | $4.65 | $114.51 | x |
| 2023-12-31 | $10.10 | $114.51 | x |
| 2024-12-31 | $8.49 | $114.51 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Arcellx Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -23.60%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -99.46%
- • Asset Turnover: 0.15x
- • Equity Multiplier: 1.56x
- Recent ROE (-23.60%) is above the historical average (-36.18%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -59.52% | 0.00% | 0.00x | 1.13x | $-9.70 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-14.70 Million |
| 2020 | -63.50% | 0.00% | 0.00x | 1.14x | $-37.15 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-51.78 Million |
| 2022 | -92.06% | -1053.37% | 0.06x | 1.53x | $-209.17 Million |
| 2023 | -14.56% | -64.08% | 0.13x | 1.70x | $-119.23 Million |
| 2024 | -23.60% | -99.46% | 0.15x | 1.56x | $-152.83 Million |
Industry Comparison
This section compares Arcellx Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Arcellx Inc (ACLX) | $440.78 Million | -59.52% | 0.49x | $4.04 Billion |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |